Sepio Capital LP Sells 3,146 Shares of Johnson & Johnson (NYSE:JNJ)

Sepio Capital LP trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,205 shares of the company's stock after selling 3,146 shares during the quarter. Sepio Capital LP's holdings in Johnson & Johnson were worth $3,830,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Gilbert & Cook Inc. raised its stake in shares of Johnson & Johnson by 3.3% during the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company's stock valued at $1,428,000 after acquiring an additional 288 shares in the last quarter. 9258 Wealth Management LLC increased its holdings in Johnson & Johnson by 2.1% during the 4th quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company's stock worth $3,454,000 after purchasing an additional 443 shares during the period. Gryphon Financial Partners LLC raised its position in Johnson & Johnson by 66.3% during the 4th quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company's stock valued at $2,244,000 after purchasing an additional 5,680 shares in the last quarter. Bank of Nova Scotia grew its position in shares of Johnson & Johnson by 132.7% during the 4th quarter. Bank of Nova Scotia now owns 582,131 shares of the company's stock worth $91,239,000 after buying an additional 331,934 shares in the last quarter. Finally, Warwick Investment Management Inc. increased its stake in shares of Johnson & Johnson by 35.9% during the fourth quarter. Warwick Investment Management Inc. now owns 2,347 shares of the company's stock valued at $368,000 after buying an additional 620 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 20th. The Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday, July 19th. TD Cowen cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a "buy" rating on the stock in a report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $173.21.

Johnson & Johnson Trading Down 0.0 %

Johnson & Johnson stock opened at $161.37 on Friday. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a market cap of $388.37 billion, a PE ratio of 10.06, a price-to-earnings-growth ratio of 2.69 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a 50-day moving average of $162.15 and a two-hundred day moving average of $154.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the previous year, the firm earned $2.80 EPS. Johnson & Johnson's revenue was up 4.3% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson's dividend payout ratio (DPR) is 30.92%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the company's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.